Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B.
- Author:
Yan-xi CHEN
1
;
Bai-yuan MAO
;
Jian-hua JIANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Alkaloids; therapeutic use; Antiviral Agents; therapeutic use; DNA, Viral; blood; Female; Hepatitis B e Antigens; blood; Hepatitis B virus; genetics; isolation & purification; Hepatitis B, Chronic; drug therapy; virology; Humans; Injections, Intramuscular; Male; Middle Aged; Polymerase Chain Reaction; Quinolizines
- From: Chinese Journal of Integrated Traditional and Western Medicine 2002;22(5):335-336
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the relationship between serum load level of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B.
METHODSForty-four patients of chronic hepatitis B were divided into two groups, the treated group was treated with oxymatrine 0.4 g/d by intramuscular injection for 3 months, the control group was treated with some liver protecting agents to estimate the therapeutic effect. The serum level of HBV-DNA was determined by quantitative polymerase chain reaction (PCR) before and after treatment.
RESULTSThe seroconversion rate of HBV-DNA and HBeAg in the treated group was 43.47% and 43.47% respectively, which was obviously better than those in the control group respectively (P < 0.05), the quantity of HBV-DNA decreased after treatment from 10(6.83 +/- 1.27) copy/ml to 10(3.35 +/- 3.08) copy/ml. Among them, in patient with HBeAg negative conversion, the pretreatment quantity of HBV-DNA was 10(6.30 +/- 1.42) copy/ml, while in those with no HBeAg negative conversion, it was 10(7.23 +/- 1.23) copy/ml, the difference was significant.
CONCLUSIONOxymatrine is effective in treating chronic hepatitis B. The therapeutic effect is better for patients with lower quantity of serum HBV-DNA.
